Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Axsome Therapeutics INC. (AXSM)

407 + Investors. Track Smart Money conviction in AXSM. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↑ +11
Streak
3Q ▲
Buyers last Q
51%

Smart Money Signals — AXSM

Based on 411 hedge funds · latest filing: 2026 Q1 · updated quarterly

📈

Buying streak — 3 quarters in a row

last 6Q
For 3 consecutive quarters, more hedge funds added AXSM than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.
🏔️

At the ownership peak (100% of max)

100% of all-time peak
411 hedge funds hold AXSM right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.
📶

Steady growth — +18% more funds vs a year ago

fund count last 6Q
+63 new funds entered over the past year (+18% YoY). Gradual, steady growth in institutional ownership is generally a healthy signal — not a speculative rush, but consistent conviction.
🟡

Slight buying edge — 51% buying

218 buying208 selling
Last quarter: 218 funds bought or added vs 208 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.
⚠️

Fewer new buyers each quarter (-16 vs last Q)

new funds entering per quarter
Funds opening this position for the first time: 53 → 50 → 87 → 71. Each quarter fewer new institutions are entering. This usually means most funds that wanted in are already in — the stock is well-known but the pool of potential new buyers is shrinking.
🔒

47% of holders stayed for 2+ years

■ 47% conviction (2yr+) ■ 24% medium ■ 29% new
192 out of 411 hedge funds have held AXSM for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.
🚀

Acceleration phase — new buyers rushing in

91 → 53 → 50 → 87 → 71 new funds/Q
New funds entering each quarter: 53 → 50 → 87 → 71. The pace of institutional discovery is accelerating sharply. This is the 'hot idea' phase — the thesis is being passed from fund to fund. You are not late — the accumulation wave is still building.
🏛️

Veteran-anchored — 53% veterans vs 32% newcomers

■ 53% veterans ■ 15% 1-2yr ■ 32% new
Entry-cohort mix of 428 holders: 228 (53%) are 2+ year veterans, 64 entered 1–2 years ago, and 136 (32%) joined within the past year. A veteran-weighted cap table skews toward institutional memory over fresh momentum.
🏆

Elite ownership — 48% AUM from top-100 funds

48% from top-100 AUM funds
58 of 407 holders are among the 100 largest funds by AUM, controlling 48% of total institutional value in AXSM. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.
4.1
out of 10
Moderate Exit Risk
Exit risk score 4.1/10 — some crowding factors present, but no critical concentration. Watch ownership trend over the next 1–2 quarters for direction.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — AXSM

In 2026 Q1, 218 hedge funds were net buyers of AXSM (71 opened a new position, 147 added to an existing one), while 208 reduced or exited (148 trimmed, 60 sold completely) — a 51% buyer ratio, indicating a slight buying edge. This marks 3 consecutive quarters of net institutional buying — a persistent conviction signal. 48% of total institutional value in AXSM is held by top-100 AUM funds, reflecting elite-tier ownership quality. Net fund flow last quarter: +11 funds (more new holders than closures). Total institutional holders: 411.

Hedge Fund Ownership: AXSM

How many hedge funds hold AXSM — quarterly history vs. share price
Quarterly hedge fund ownership of AXSM vs. share price

Market Analysis: AXSM

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: AXSM

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy Axsome Therapeutics INC. (AXSM) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much AXSM has moved relative to its sector benchmark (XLV) since the 2026 Q2 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End June 30, 2026 · 46d ago
AXSM
-12.7%
XLV
+5.5%

AXSM outperformed XLV by -18.2% since June 30, 2026.

Since 13F Filing Date August 14, 2026 · 1d ago
AXSM
+0.0%
XLV
+0.0%

Since the filing became public, AXSM outperformed XLV by +0.0% .

Interpretation: The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference. Learn more →

Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

29 top-rated funds 6 high-conviction
Consensus
6.4
/ 10
breadth
×
Elite
4.5
/ 10
conviction
Hedge Fund Positioning: AXSM
2026 Q2 Stats Unlock in 4 days 407 + Investors

Track Smart Money conviction in AXSM. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q1) Prior (2025 Q4) Change
Funds Holding 407 400 1.75%
13F Shares 39M 39M -0.42%
Total Value $6.34B $6.82B -6.92%
New Positions 71 87 -16
Increased Positions 144 149 -5
Closed Positions 60 40 +20
Reduced Positions 142 115 +27
Total Calls 12 14 -14.29%
Total Puts 9 11 -18.18%
PUT/CALL Ratio 0.75 0.79 Neutral

Statistics: AXSM

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q2)

407 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in AXSM. Verified SEC 13F-HR filings.

QUARTER:
2026 Q2 filings are still coming in. Only funds that have filed so far are shown — top holders may not have reported yet. Full 13F data typically settles by ~50 days after quarter-end.
Top 25 AXSM holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 Alethea Capital Management, LLC 65.78% 648,756 $158.8M
2 Superstring Capital Management LP 8.33% 53,916 $13.2M
3 Tri Locum Partners LP 6.60% 219,308 $53.7M
4 First Turn Management, LLC 5.72% 218,415 $53.5M
5 Panoramic Capital, LLC 4.63% 44,000 $10.8M
6 PFM Health Sciences, LP 4.61% 219,596 $53.8M
7 Iridian Asset Management LLC/Ct 4.03% 47,924 $11.7M
8 Ally Bridge Group (NY) LLC 3.57% 16,493 $4.0M
9 Occam Crest Management LP 3.52% 29,800 $6.8M
10 Science & Technology Partners, L.P. 3.01% 73,040 $17.9M
11 Ishara Investments LP 2.95% 16,400 $4.0M
12 Integral Health Asset Management, LLC 2.90% 300,000 $73.4M
13 Eagle Health Investments LP 2.64% 65,051 $15.9M
14 Deep Track Capital, LP 2.49% 700,000 $171.3M
15 KVP Capital Advisors, LP 2.16% 12,000 $2.9M
16 1492 Capital Management LLC 2.12% 29,307 $7.2M
17 Sofinnova Investments, Inc. 2.03% 160,429 $39.3M
18 Catalio Capital Management, LP 1.99% 43,182 $10.6M
19 Privium Fund Management B.V. 1.80% 39,944 $9.8M
20 Rhenman & Partners Asset Management AB 1.46% 63,050 $15.4M
21 Nicholas Investment Partners, LP 1.36% 98,974 $24.2M
22 AlphaCentric Advisors LLC 1.35% 6,531 $1.6M
23 Tetragon Partners GP Ltd 1.35% 35,000 $8.6M
24 HighVista Strategies LLC 1.13% 20,183 $4.9M
25 Lisanti Capital Growth, LLC 1.12% 20,825 $5.1M
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Axsome Therapeutics INC. (AXSM)

What does the Smart Money Trend signal show for AXSM?

Buying streak — 3 quarters in a row: For 3 consecutive quarters, more hedge funds added AXSM than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for AXSM?

Slight buying edge — 51% buying: Last quarter: 218 funds bought or added vs 208 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

What is the fund quality score for AXSM holders?

Elite ownership — 48% AUM from top-100 funds: 58 of 407 holders are among the 100 largest funds by AUM, controlling 48% of total institutional value in AXSM. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.

How long have hedge funds held AXSM?

47% of holders stayed for 2+ years: 192 out of 411 hedge funds have held AXSM for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

Is it too late to buy Axsome Therapeutics INC. (AXSM) following the 2026 Q2 hedge fund 13F filings?

As of today, AXSM has moved +0.0% since the 2026 Q2 13F filing date (August 14, 2026), compared to +0.0% for the XLV sector ETF — an outperformance of +0.0%. Since the quarter end (June 30, 2026), AXSM has gained -12.7% vs +5.5% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →